THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

IKONOMIDOU, Hrissanthi

AUG 2 2 2001

**TECH CENTER 1600/2900** 

Serial No.

: 09/830,354

Filed

: 25 April 2001

Title: NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

**Assistant Commissioner for Patents** Washington, D. C. 20231

Sir:

	CITEI	ED MATERIALS						
1449.	Applic	Applicant(s) wish to disclose the following information, listed in the attached form PTO-						
		Copies of materials listed but not attached were cited in parent application Serial No.						
	$\boxtimes$	Copies of materials listed but not attached were cited in an International Sear Report dated 14 February 2000; receipt of any International Search Report a copies of references were confirmed by the PCT International Division of the UPTO in the Notice of Acceptance mailed 14 June 2001.						
		Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.						
		Also included are the pending U.S. applications listed below, copies of which are attached:						
	<u>FEES</u>							
	$\boxtimes$	No fee is required for this Information Disclosure Statement because:						
		This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;						
		☐ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;						
		This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that						

	A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).									
	A check is attached: This Information Disclosure Statement is being filed after mailing date of a notice of allowance under § 1.311 but before the payment of the fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.									
CERT	CERTIFICATION									
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.									
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.									
DEPOSIT ACCOUNT										
If appro	opriate, attached is a check in the amount of <u>\$</u> . However, the Commissioner is									
hereby authoriz	ed to charge fees under 37 CFR 1.16 and 1.17 which may be required to									
facilitate this fil	ing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are									
attached for this	s purpose.									
	Respectfully submitted,									
MILLEN, WHI										

Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Date: 20 August 2001

							Snee	tlof			
Form l	PTO-14				ATTY. DKT. NO.		SERIAL NO.				
		1	PATENT AND TRADEM ARK OFFICE		HRISS-1		09/830354				
					APPLICANT						
Jo\F	ENE'S	RMATION I BY	DISCLOSUI APPLICAN	RE STATEMENT	IKONOMIDOU						
<b>P</b>			eral sheets if necessary)		FILING DATE		GROUP				
<u> </u>			Tal sheets if necessary,		April 25, 2001						
TEN	. AR		U.S	S. PATENT DOCUMENTS	S	<u>.</u>					
Examin Initial	ter	Document Number	Date	Name	Class	Subclass	Filing	, Date			
	AA	4885171	12/5/1989	SURENDRA SEHGAL N							
	AB						11 / [	$\overline{\Box}$			
	AC			·		<b>NEO</b>					
	AD					ALIG	2 2 20	01			
	AE	,									
	AF		ļ			CH CEN	TER 160	101590			
	AG	<u> </u>	<u> </u>								
		·	FORE	IGN PATENT DOCUME	NTS						
Examiner Initial		Document Number	Date	Country	Class	Subclass	Trans Yes	lation No			
	AM	0778023	6/11/1997	EP			ies	140			
	AN	0432994	6/19/1991	EP			<del> </del>	<b>-</b>			
	AO	0.52551	0,13,1331	DI .							
	AP						1	<u> </u>			
	AQ										
	AR						<b>—</b>				
	AS					,					
	AT										
	O'	THER DOCU	MENTS (In	cluding Author, Title, Dat	e, Pertinent 1	Pages, Etc	:.)				
	AU	S.BEN-ELIYAHU: "The NMDA receptor antagonist MK-801 blocks nonopioid stress induced analgesia and decreases tumor metastasis in the rat" PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY, vol 36, 1993, pg 293-298									
	AV	N.SEILER: "Polyamine sulfonamides with NMDA antagonist properties are potent calmodulin antagonists and cytotoxic agents" INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY vol 30 no. 3 March 1998 pg 393-406									
	AW										
	AX										
	AY	KYAMADA: "Clinical and experimental studies on the antileukemic action of Lasparaginase" COLLOQ.INT.CENT.NAT.RECH.SCI. no. 197, 1971, pg 311-322									
	AZ				<del></del>						
Examin	er		Date Con	sidered							
jb:K:\HRISS	\1449.wp	d.HRISS1.wpd									